Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review

  • ID: 1290947
  • SWOT Analysis
  • Region: Global
  • 68 pages
  • GlobalData
  • Valeant
1 of 5

FEATURED COMPANIES

  • AIM Therapeutics Inc
  • Endo International Plc
  • GTx Inc
  • Maruho Co Ltd
  • Mylan NV
  • Pfizer Canada Inc
  • MORE
Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Valeant Pharmaceuticals International Inc (Valeant) develops, manufactures and markets several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Valeant is headquartered in Laval, Quebec, Canada.

Valeant Pharmaceuticals International Inc Key Recent Developments

Feb 28, 2018: Valeant Announces Fourth-Quarter And Full-Year 2017 Financial Results
Nov 15, 2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results
Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts
Sep 05, 2017: Québec Superior Court Grants Leave under Québec Securities Act in Valeant Pharmaceuticals Securities Class Action

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AIM Therapeutics Inc
  • Endo International Plc
  • GTx Inc
  • Maruho Co Ltd
  • Mylan NV
  • Pfizer Canada Inc
  • MORE
Section 1 - About the Company
  • Valeant Pharmaceuticals International Inc - Key Facts
  • Valeant Pharmaceuticals International Inc - Key Employees
  • Valeant Pharmaceuticals International Inc - Key Employee Biographies
  • Valeant Pharmaceuticals International Inc - Major Products and Services
  • Valeant Pharmaceuticals International Inc - History
  • Valeant Pharmaceuticals International Inc - Company Statement
  • Valeant Pharmaceuticals International Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Valeant Pharmaceuticals International Inc - Business Description
  • Business Segment: Bausch + Lomb/International
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Branded Rx
  • Overview
  • Performance
  • Business Segment: US Diversified Products
  • Overview
  • Performance
  • Geographical Segment: Australia
  • Performance
  • Geographical Segment: Brazil
  • Performance
  • Geographical Segment: Canada
  • Performance
  • Geographical Segment: China
  • Performance
  • Geographical Segment: Egypt
  • Performance
  • Geographical Segment: France
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Mexico
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: Poland
  • Performance
  • Geographical Segment: Russia
  • Performance
  • Geographical Segment: The UK
  • Performance
  • Geographical Segment: The US and Puerto Rico
  • Performance
  • R&D Overview
  • Valeant Pharmaceuticals International Inc - Corporate Strategy
  • Valeant Pharmaceuticals International Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Valeant Pharmaceuticals International Inc - Strengths
  • Valeant Pharmaceuticals International Inc - Weaknesses
  • Valeant Pharmaceuticals International Inc - Opportunities
  • Valeant Pharmaceuticals International Inc - Threats
  • Valeant Pharmaceuticals International Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Valeant Pharmaceuticals International Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 15, 2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
  • Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results
  • Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts
  • Sep 05, 2017: Québec Superior Court Grants Leave under Québec Securities Act in Valeant Pharmaceuticals Securities Class Action
  • Aug 16, 2017: Valeant Receives FDA Confirmation Of Voluntary Action Indicated Inspection Classification For Tampa Facility
  • Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results
  • Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International
  • Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International
  • Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications
  • Jun 19, 2017: John Paulson Joins Valeant Board Of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Valeant Pharmaceuticals International Inc, Key Facts
  • Valeant Pharmaceuticals International Inc, Key Employees
  • Valeant Pharmaceuticals International Inc, Key Employee Biographies
  • Valeant Pharmaceuticals International Inc, Major Products and Services
  • Valeant Pharmaceuticals International Inc, History
  • Valeant Pharmaceuticals International Inc, Other Locations
  • Valeant Pharmaceuticals International Inc, Subsidiaries
  • Valeant Pharmaceuticals International Inc, Key Competitors
  • Valeant Pharmaceuticals International Inc, Ratios based on current share price
  • Valeant Pharmaceuticals International Inc, Annual Ratios
  • Valeant Pharmaceuticals International Inc, Annual Ratios
  • Valeant Pharmaceuticals International Inc, Annual Ratios
  • Valeant Pharmaceuticals International Inc, Interim Ratios
  • Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Valeant Pharmaceuticals International Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Valeant Pharmaceuticals International Inc, Performance Chart (2013 - 2017)
  • Valeant Pharmaceuticals International Inc, Ratio Charts
  • Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AIM Therapeutics Inc
  • Endo International Plc
  • GTx Inc
  • Maruho Co Ltd
  • Mylan NV
  • Opiant Pharmaceuticals Inc
  • Pfizer Canada Inc
  • Polydex Pharmaceuticals Ltd
  • Sirona Biochem Corp
  • Stratus Pharmaceuticals Inc
  • Xenon Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll